Drug Trial Radar · NCT05095701
An Immunity Persistence Study of Live Attenuated Varicella Vaccine
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
703
Planned (sponsor's estimate)
Start
Dec 18, 2021
Primary completion
Dec 19, 2021
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This an open phase Ⅳ clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 5 and 8 years after primary immunization with live attenuated varicella vaccine.
Conditions
- Varicella
Interventions
Investigational Live Attenuated Varicella VaccineBiological
The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.
Placebo (Freeze Dired Dilution)Biological
The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immunogenicity index-seropositive rates of varicella antibodyTime frame: 5 years after primary immunization
- Immunogenicity index-GMT of varicella antibodyTime frame: 5 years after primary immunization
- Immunogenicity index-the seropositive rates of varicella antibodyTime frame: 8 years after primary immunization
- Immunogenicity index-the GMT of varicella antibodyTime frame: 8 years after primary immunization
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Xiangcheng County Center for Disease Control and Prevention
Xuchang, Henan, China
Biyang County Center for Disease Control and Prevention
Zhumadian, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.